COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.
作者信息
Garcia Pablo, Anand Shuchi, Han Jialin, Montez-Rath Maria E, Sun Sumi, Shang Tiffany, Parsonnet Julie, Chertow Glenn M, Schiller Brigitte, Abra Graham
机构信息
Department of Medicine (Nephrology), Stanford University, Stanford, California.
Medical Clinical Affairs, Satellite Healthcare Inc., San Jose, California.
出版信息
J Am Soc Nephrol. 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13.
Abstract
摘要
相似文献
1
COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.接受透析患者的新冠疫苗类型与体液免疫反应
J Am Soc Nephrol. 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13.
2
Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.透析患者对基于mRNA与腺病毒载体的SARS-CoV-2疫苗的体液反应。
Clin J Am Soc Nephrol. 2021 Nov;16(11):1720-1722. doi: 10.2215/CJN.06450521. Epub 2021 Jul 26.
3
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
4
Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.血液透析患者接种 mRNA-1273 和 BNT162b2 新冠病毒疫苗的体液和细胞免疫反应。
Am J Kidney Dis. 2021 Oct;78(4):571-581. doi: 10.1053/j.ajkd.2021.06.002. Epub 2021 Jun 24.
5
Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.COVID-19 信使 RNA 疫苗在功能性 B 细胞缺陷原发性免疫缺陷患者中的免疫原性和耐受性。
J Allergy Clin Immunol. 2022 Mar;149(3):907-911.e3. doi: 10.1016/j.jaci.2021.11.022. Epub 2021 Dec 21.
6
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.异基因造血细胞移植受者接种2剂和3剂SARS-CoV-2 mRNA疫苗后的抗体反应。
Blood. 2022 Jan 6;139(1):134-137. doi: 10.1182/blood.2021014232.
7
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.肾移植受者中 SARS-CoV-2 BNT162b2（tozinameran）疫苗加强接种后体液和细胞免疫受损。
J Clin Invest. 2021 Jul 15;131(14). doi: 10.1172/JCI150175.
8
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.血液透析患者中 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗的真实世界有效性和免疫原性。
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
9
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.血液透析患者和肾移植受者队列中 SARS-CoV-2 mRNA 疫苗接种后的体液反应。
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158. doi: 10.1681/ASN.2021040490. Epub 2021 Jun 16.
10
Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.COVID-19 疫苗接种三剂后，HIV 感染者体内针对 SARS-CoV-2 刺突蛋白的效价和演变。
J Microbiol Immunol Infect. 2024 Aug;57(4):554-563. doi: 10.1016/j.jmii.2024.02.004. Epub 2024 Feb 26.
引用本文的文献
1
18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting.中低收入环境下接受异源 3 剂接种（AZD-1222-AZD-1222-BNT162b2）的血液透析患者 18 个月内 SARS-CoV-2 中和抗体的纵向动态变化。
BMC Nephrol. 2024 May 22;25(1):176. doi: 10.1186/s12882-024-03599-7.
2
Safety and Immunogenicity of the Convacell Recombinant N Protein COVID-19 Vaccine.康瓦塞尔重组N蛋白新冠疫苗的安全性和免疫原性
Vaccines (Basel). 2024 Jan 19;12(1):100. doi: 10.3390/vaccines12010100.
3
COVID-19 incidence and outcomes among patients with kidney replacement therapy.接受肾脏替代治疗的患者中新冠病毒疾病2019的发病率及治疗结果
Kidney Res Clin Pract. 2023 Sep;42(5):649-659. doi: 10.23876/j.krcp.22.240. Epub 2023 Sep 27.
4
Serial SARS-CoV-2 Antibody Titers in Vaccinated Dialysis Patients: Prevalence of Unrecognized Infection and Duration of Seroresponse.接种疫苗的透析患者中SARS-CoV-2抗体滴度的系列研究：未识别感染的患病率和血清反应持续时间
Kidney Med. 2023 Aug 25;5(11):100718. doi: 10.1016/j.xkme.2023.100718. eCollection 2023 Nov.
5
COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.维持性肾脏替代治疗患者的 COVID-19 疫苗接种：免疫反应、真实世界疗效及对未来的启示。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S46-S54. doi: 10.1093/infdis/jiad162.
6
Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA型严重急性呼吸综合征冠状病毒2疫苗接种后长期血液透析患者有效细胞免疫和体液免疫反应的维持
Pharmaceuticals (Basel). 2023 Apr 11;16(4):574. doi: 10.3390/ph16040574.
7
Effects of SARS-CoV-2 vaccination on the severity of COVID-19 infection in patients on chronic dialysis.SARS-CoV-2 疫苗接种对慢性透析患者 COVID-19 感染严重程度的影响。
J Nephrol. 2023 Jun;36(5):1321-1328. doi: 10.1007/s40620-023-01617-9. Epub 2023 Apr 5.
8
Availability and prioritisation of COVID-19 vaccines among patients with advanced chronic kidney disease and kidney failure during the height of the pandemic: a global survey by the International Society of Nephrology.在大流行高峰期，患有晚期慢性肾脏病和肾衰竭的患者中 COVID-19 疫苗的供应和优先排序：国际肾脏病学会的全球调查。
BMJ Open. 2022 Dec 30;12(12):e065112. doi: 10.1136/bmjopen-2022-065112.
9
COVID-19 Vaccination in Kidney Transplant Candidates and Recipients.肾移植候选者和接受者中的新冠病毒疫苗接种
Vaccines (Basel). 2022 Oct 27;10(11):1808. doi: 10.3390/vaccines10111808.
10
Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.SGLT-2 抑制剂在慢性肾脏病治疗中的价值：临床与实践意义。
Wien Klin Wochenschr. 2023 Feb;135(3-4):97-109. doi: 10.1007/s00508-022-02096-x. Epub 2022 Oct 17.
本文引用的文献
1
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.
2
Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.血液透析患者接种3剂BNT162b2 mRNA新冠疫苗后的体液免疫反应。
Kidney Int. 2021 Sep;100(3):702-704. doi: 10.1016/j.kint.2021.06.025. Epub 2021 Jun 30.
3
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
4
Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis.接受透析治疗的患者对新冠疫苗接种的抗体反应。
J Am Soc Nephrol. 2021 Oct;32(10):2435-2438. doi: 10.1681/ASN.2021050611. Epub 2021 Jun 11.
5
Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study.成人肾脏替代治疗患者 COVID-19 的发病情况、特征和结局：一项区域登记研究。
J Am Soc Nephrol. 2021 Feb;32(2):385-396. doi: 10.1681/ASN.2020060875. Epub 2020 Nov 5.
Zotero 插件